TIDE algorithm indicated that low-risk BLCA patients may be responsive to PD-1 blockade therapy, and high-risk BLCA patients may be responsive to CTLA4 blockade therapy. The gene discussed is CTLA4; the disease is bladder transitional cell carcinoma.